Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $66.95 per share under a pre-arranged Rule 10b5-1 plan.
Summary
- Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), reported a sale of common stock.
- The transaction involved the disposition of 26 shares of Guardant Health common stock.
- The shares were sold at a price of $66.95 per share.
- The sale was executed on October 17, 2025.
- Following this transaction, Myrtle S. Potter beneficially owns 18,324 shares of Guardant Health common stock.
- The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: The transaction is a small, pre-planned insider sale under a Rule 10b5-1 plan, which is generally considered a neutral event and does not reflect a change in company fundamentals or management's confidence.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive positioning. Insider sales under Rule 10b5-1 plans are common and generally indicate pre-scheduled liquidity events rather than a reaction to new company-specific or industry-wide developments.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan. This indicates the sale was pre-arranged to comply with insider trading regulations, mitigating concerns about sales based on material non-public information. | 10/17/2025 | Positive, as it demonstrates adherence to best practices for insider trading compliance and transparency. |
Stakeholder Impact
- Shareholders: The sale of 26 shares by a director is a very small transaction and is unlikely to have any material impact on the company's stock price or shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/17/2025 | Date of transaction for the sale of common stock. |
| 10/20/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Guardant Health, GH, Insider Transaction, Form 4, Stock Sale, Director, Myrtle S. Potter, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.